Methods and compositions for the detection of cancer

A composition for detecting a prostate cancer comprising:

• a) thapsigargin (TG) or a thapsigargin analog;
• b) a phenolic linker comprising a radiolabel;
• and
• c) a peptide cleavable by a protein selected from:
• i) prostate specific membrane antigen (PSMA);
• ii) prostate specific antigen (PSA);
• and
• iii) human glandular kallikrein 2 (hK2)
• wherein said phenolic linker is conjugated to said thapsigargin or thapsigargin analogue.

A composition for detecting a cancer comprising:

• a) thapsigargin (TG) or a thapsigargin analog;
• b) a phenolic linker comprising a radiolabel;
• and
• c) a peptide cleavable by prostate specific membrane antigen (PSMA),
• wherein said phenolic linker is conjugated to said thapsigargin or thapsigargin analogue.

A method of imaging or treating a subject having cancer or suspected of having cancer comprising administering to the subject a composition comprising:

• a) thapsigargin (TG) or a thapsigargin analog;
• b) a phenolic linker comprising a radiolabel;
• and
• c) a peptide cleavable by prostate specific membrane antigen (PSMA);
• wherein said phenolic linker is conjugated to said thapsigargin or thapsigargin analogue.

A method of imaging or treating a subject having prostate cancer or suspected of having prostate cancer comprising administering to the subject a composition comprising:

• a) thapsigargin (TG) or a thapsigargin analog;
• b) a phenolic linker comprising a radiolabel;
• and
• c) a peptide cleavable by a protein selected from:
• i) prostate specific membrane antigen (PSMA);
• ii) prostate specific antigen (PSA);
• and
• iii) human glandular kallikrein 2 (hK2)
• wherein said phenolic linker is conjugated to said thapsigargin or thapsigargin analogue.